O lder adults are living longer and taking more medications. Adverse drug reactions (ADRs) have been described as 1 of the top 5 greatest threats to the health of this population. 1 Prescribing medications to older adults with a known risk of ADRs has been linked to greater healthcare use and death. [1] [2] [3] It is important to identify and reduce the use of medications associated with more risks than benefits in older adults.
The 2015 American Geriatric Society (AGS) Beers Criteria lists potentially inappropriate medications (PIMs) for use in elderly adults because of the probability that they will cause adverse effects in this population. 4 Mark Beers, the geriatrician who conducted the influential research on medication use in older adults, defined Beers Criteria medications as "medications that pose greater risks than they provide in therapeutic value or those medications for which a safer alternative is available." 4 One potential way to avoid ADRs and inappropriate medication use in older adults is to discontinue or "deprescribe" medications that are unnecessary, ineffective, or inappropriate, 5 but the literature on deprescribing of these medications is limited.
This research was conducted to evaluate the effect an interdisciplinary team (IDT) including a clinical pharmacy specialist (CPS) would have on deprescribing of PIMs in older adults. Veterans aged 85 and older are the fastest growing subpopulation of Veteran Health Administration (VHA) beneficiaries. 6 Demand for geriatric primary care programs first arose in 2009 and transitioned to Geriatric Patient-Aligned Care Teams (GeriPACT) to address limitations to providing care for this population. 6 The Lexington Veterans Affairs Medical Center (VAMC) first established a GeriPACT clinic in 2015.
An IDT that includes a CPS follows individuals who receive care in the GeriPACT clinic. We hypothesized that veterans receiving care in the GeriPACT cohort would have more PIMs\ deprescribed than those receiving UC because of inclusion of a CPS as a core member of the IDT.
METHODS

Study Design and Participant Selection
After institutional review board approval was obtained, a retrospective cohort study was performed using the computerized medical record system at the Lexington VAMC. Veterans aged 80 and older who had filled a PIM at least 90 days before a GeriPACT appointment from January 1, 2015, to September 6, 2017, were included in this study (n = 393). Veterans were excluded if their PIM was discontinued according to the Pharmacy and Therapeutics protocol because it had not been filled in an 8-month period, was discontinued during a hospitalization, or was prescribed for a 30-day supply or less with no refills (n = 109). Using a random number generator, individuals receiving UC were individually matched, resulting in our control group. Individuals receiving UC were excluded using the same exclusion criteria as for individuals undergoing GeriPACT and if they were involved in the pharmacy-driven Psychotropic Drug Safety Initiative. The final analysis included 284 individuals in each cohort for a total of 568 participants.
Demographic information collected included age, sex, race, weight, height, body mass index (BMI), and diagnosis of chronic disease states as documented in the individual's problem list (Table 1) . Information was recorded on PIMs and their medication class, discontinuation date, dose reductions; documentation of a risk-benefit discussion; and the number of provider visits that each participant had during the study time period was recorded.
PIMs (Table 2) were defined as Table 2 and Table 7 of the American Geriatric Society (AGS) Beers Criteria plus aspirin 325 mg.
Outcomes
The primary outcome of this study was to determine whether an IDT including a CPS resulted in greater deprescribing of PIMs for older adults than UC. Successful deprescribing was defined as discontinuation of a PIM from the outpatient medication list. Secondary outcomes included identification of the PIM class deprescribed most often, dose reductions of PIMs if not discontinued, and documentation of a discussion between a provider or pharmacist and a participant regarding the risks and benefits of not discontinuing PIMs.
Data Analysis
Baseline characteristics and primary and secondary objectives of the cohorts were compared using chi-square tests for categorical variables and t-tests for continuous variables. Alpha was set at 0.05, and statistical significance was defined as a p < .05.
RESULTS
Cohort characteristics are presented in Table 1 . For Geri-PACT participants, average age at first visit was 85.1, 89.8% were Caucasian, and 99.6% were male. UC participants had an average age at first visit of 84.4, 90.1% were Caucasian, and 99.0% were male. GeriPACT participants averaged 2.7 provider visits during the study period, and UC participants averaged 3.7 provider visits (p < .001). Of the chronic diseases that were recorded, GeriPACT participants were more likely to be diagnosed with Parkinson's disease (p = .01), coronary artery disease (p = .03), dementia (p = .03), depression (p = .02), and peripheral vascular disease (p = .04). UC participants were more likely to be diagnosed with hyperlipidemia (p = .007). There were no significant differences between the cohorts in any other chronic diseases (Table 1) . Each cohort had 284 participants; GeriPACT participants were prescribed 451 PIMs, and UC participants were prescribed 454 PIMs during the study period. For the primary outcome, 121 (26.8%) PIMs were deprescribed in the GeriPACT cohort and (73) 16.1% in the UC cohort (p <.001). Deprescribing according to medication class is shown in Table 3 . Nonsteroidal antiinflammatory drugs (NSAIDs) were the PIM class most commonly deprescribed in the GeriPACT cohort (56%). Antihistamines were the PIM class most commonly deprescribed in the UC cohort (31.6%); antipsychotics were discontinued 50% of the time, but UC participants in this study filled only 2 antipsychotic PIMs. The GeriPACT cohort had a 34.0% reduction in nonselective alpha-blockers and the UC cohort a16.5% reduction. Of PIMs not discontinued, 9.7% (n = 32) were dose reduced in GeriPACT and 2.8% (n = 11) in UC (p < .001). Documentation of discussion of risks and benefits between a provider and a participant or a pharmacist and a participant after which a PIM was not discontinued occurred in 65.2% (n = 215) of the GeriPACT cohort and 0.003% (n = 1) of the UC cohort (p < .001).
DISCUSSION
The VHA developed GeriPACT to provide integrated, interdisciplinary assessment and longitudinal management of the healthcare needs of a spectrum of elderly, particularly vulnerable veterans who are aging with complex chronic diseases and often cognitive decline. 6 At the Lexington VAMC, the GeriPACT team is a collaborative partnership of healthcare professionals consisting of a provider (medical doctor, nurse practitioner, physician assistant), a registered nurse, a licensed practical nurse, a social worker, a CPS, a clinical associate, and clerical staff. The CPS meets with each individual to discuss and review medications during each appointment. In contrast to GeriPACT, UC consists of a primary care provider, registered nurse, licensed practical nurse, and administrative associate as core members of a PACT. Discipline-specific team members often include a social worker and a CPS per referral who are often used for chronic disease management. This study of veterans aged 80 and older taking PIMs found that those who the GeriPACT team followed had a statistically and clinically significantly greater reduction in PIM use than those receiving UC. Furthermore, for PIMs that were not deprescribed, there were significantly more dose reductions and documentation of discussions of their risks and benefits in the GeriPACT cohort.
Participant characteristics were similar between the cohorts ( Table 1 ). The GeriPACT cohort had many participants with comorbid conditions such as dementia, Parkinson's disease, peripheral vascular disease, coronary artery disease, and depression, which was to be expected because they are specified qualifying criteria for inclusion in the GeriPACT clinic. An unexpected difference between the 2 cohorts was the number of provider visits during the study period; GeriPACT participants had significantly fewer primary clinic visits than UC participants.
Most PIMs identified in this study were NSAIDs, anticholinergics, peripheral alpha-blockers, and proton pump inhibitors . An example of a common deprescribing intervention that the GeriPACT CPS made was conversion of nonselective to uroselective alpha-blockers used in the treatment of benign prostatic hypertrophy. These nonselective agents may cause orthostatic hypotension, common in older adults. 7 Studies have shown that uroselective agents have less potential to cause orthostatic hypotension. 8 These recommendations may contribute to reduced rates of falls, but this was not an outcome of this study.
Regarding PIM classes deprescribed most often, NSAIDs had the highest deprescribing rate in the GeriPACT cohort. This included the dose reduction of aspirin. Research suggests that aspirin maximally inhibits cyclooxygenase-1 at doses of 81 mg or less. There is empirical evidence that risk of major and minor bleeding increases with increasing aspirin dose, with no added benefit in additional platelet inhibition. 9 Proton pump inhibitors had the lowest deprescribing rates in each cohort. Approximately 17% of veterans in each cohort had atrial fibrillation; we hypothesize that use of anticoagulants in these veterans resulted in less deprescribing.
There are other barriers to deprescribing. One example is being followed by multiple medical specialists. Providers are often hesitant to deprescribe a medication originating from another provider. Another critical limitation is perception. Individuals often perceive that discontinuation of a medication may result in a return of symptoms or worsening of outcomes. This is where the role of the CPS on the healthcare team is important. Pharmacists are trained as medication experts, allowing a focus on education and documentation of the risks and benefits of PIMs, which frequent documentation of discussion of risks and benefits in the GeriPACT cohort demonstrates.
A strength of this study is the study population. Older adults are often underrepresented in trials. The number of older adults is expected to increase exponentially over the coming decades, which will require healthcare providers to identify strategies to improve health care and education for older adults living longer with multiple comorbid conditions and medications. Prevention of prescribing PIMs in this population would be ideal. The Enhancing the Quality of Prescribing Practices for older veterans discharged from the Emergency Department (EQUiPPED) study aimed to reduce the number of prescriptions for PIMS written at emergency department discharge for older veterans. 10 EQUiPPED was an educational pre-prescribing intervention, which differs from our research which is a deprescribing model intervention.
In the United States, there is a lack of guidelines to assist in PIM deprescribing. There are a few published deprescribing algorithms. 11, 12 Tools to implement these algorithms are needed to aid clinicians in reducing PIMs. In the meantime, this research highlights the use of a CPS in the healthcare setting to assist in reduction of PIMs in older adults.
Limitations of this study include the retrospective design, with parts of the data dependent on documentation. In addition, the time frame between GeriPACT clinic patient enrollment date and data collection was insufficient to evaluate clinical outcomes. Additional research is needed to determine the effect of deprescribing PIMs on ADRs, healthcare use, and healthcare costs.
CONCLUSION
The use of an IDT that included a CPS significantly reduced the number of PIMs in an older veteran cohort. The IDT with a CPS also led to significantly more PIM dose reductions and documentation of discussion of the risks and benefits of continued use of PIMs not deprescribed. Together, these findings suggest that using a CPS in the routine care of older veterans assists with deprescribing. Additional research is needed to determine whether reduction of PIMs reduces the number of ADRs or has positive outcomes on healthcare use and cost.
